By 2010, half of all FDA drug approvals will be in the area of specialty drugs.
By 2010, half of all FDA drug approvals will be in the area of specialty drugs. That forecast comes from Richard Faris, Ph.D., R.Ph., VP of Health Outcomes Solutions at Accredo Health Group. Speaking at the NACDS pharmacy and technology conference in Boston this month, Faris added that the biologics' share of the pharmaceutical market is expected to increase from 15.3% in 2005 to 21.6% in 2010. The targets of specialty drugs in development range from multiple sclerosis to oncology, hepatitis C, and pulmonary arterial hypertension.